SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BRADBURY DANIEL

(Last)

(First)

(Middle)

C/O CASTLE BIOSCIENCES, INC.

820 S. FRIENDSWOOD DRIVE, SUITE 201

(Street)

FRIENDSWOOD

77546

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2019

3. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to buy)	⁽¹⁾	07/23/2019	Common Stock	30,895	$16	D
Series A Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	112,307	⁽²⁾	I	By LLC⁽³⁾
Series B Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	128,839	⁽²⁾	I	By LLC⁽³⁾
Series C Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	23,572	⁽²⁾	I	By LLC⁽³⁾
Series D Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	140,932	⁽²⁾	I	By LLC⁽³⁾
Series E-1 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	138,250	⁽²⁾	I	By LLC⁽³⁾
Series E-2 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	44,801	⁽²⁾	I	By LLC⁽³⁾
Series E-3 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	39,855	⁽²⁾	I	By LLC⁽³⁾
Series F Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	209,005	⁽²⁾	I	By LLC⁽³⁾
Convertible Promissory Note	⁽⁴⁾	⁽⁴⁾	Common Stock	$874,537.48	⁽⁴⁾	I	By LLC⁽³⁾

Explanation of Responses:

1. 25% of the shares shall vest on August 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.

2. All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration at a rate of 1 share of Common Stock for each 1.219 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

3. Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares.

4. The Reporting Person is the managing member of BioBrit, LLC, and has voting and investment power over the shares. The principal amount of the Convertible Promissory Note held by the Reporting Person is $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") will automatically convert into the number of shares of Common Stock that is equal to the Conversion Amount as of the closing date divided by 80% of the IPO price per share.

Remarks:

	/s/ Greg Acosta, Attorney-in-fact	07/24/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.